- Home
- INTS vs GROW Comparison
INTS vs GROW Comparison
Compare INTS & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- GROW
- Stock Information
- Founded
- INTS 2012
- GROW 1968
- Country
- INTS United States
- GROW United States
- Employees
- INTS N/A
- GROW N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- GROW Investment Managers
- Sector
- INTS Health Care
- GROW Finance
- Exchange
- INTS Nasdaq
- GROW Nasdaq
- Market Cap
- INTS 35.3M
- GROW 32.9M
- IPO Year
- INTS 2023
- GROW N/A
- Fundamental
- Price
- INTS $2.33
- GROW $2.23
- Analyst Decision
- INTS Strong Buy
- GROW
- Analyst Count
- INTS 3
- GROW 0
- Target Price
- INTS $8.50
- GROW N/A
- AVG Volume (30 Days)
- INTS 18.1K
- GROW 26.7K
- Earning Date
- INTS 03-21-2025
- GROW 05-08-2025
- Dividend Yield
- INTS N/A
- GROW 4.02%
- EPS Growth
- INTS N/A
- GROW N/A
- EPS
- INTS N/A
- GROW 0.04
- Revenue
- INTS N/A
- GROW $9,421,000.00
- Revenue This Year
- INTS N/A
- GROW N/A
- Revenue Next Year
- INTS N/A
- GROW N/A
- P/E Ratio
- INTS N/A
- GROW $60.71
- Revenue Growth
- INTS N/A
- GROW N/A
- 52 Week Low
- INTS $1.50
- GROW $2.21
- 52 Week High
- INTS $5.78
- GROW $2.95
- Technical
- Relative Strength Index (RSI)
- INTS 53.36
- GROW 16.73
- Support Level
- INTS $2.17
- GROW $2.27
- Resistance Level
- INTS $2.43
- GROW $2.35
- Average True Range (ATR)
- INTS 0.20
- GROW 0.04
- MACD
- INTS 0.01
- GROW -0.02
- Stochastic Oscillator
- INTS 73.08
- GROW 5.85
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.